SEEDO consensus 2007 for the evaluation of overweight and obesity and the establishment of therapeutic intervention criteria;Consenso SEEDO 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica

Revista Espanola de Obesidad

Volumn 5, Issue 3, 2007, Pages 135-175

  Rubio Hererra, Miguel A ^a   Salas Salvadó, Jordi ^b   Barbany, Montserrat ^b   Moreno, Basilio ^b   Aranceta, Javier ^b   Bellido, Diego ^b   Blay, Vicente ^b   Carraro, Rafaelle ^b   Formiguera, Xavier ^b   Foz, Marius ^b   De Pablos, Pedro Luis ^b   García Luna, Pedro Pablo ^b   Griera, José Luis ^b   De La Torre, Martín López ^b   Martínez, José Alfredo ^b   Remesar, Xavier ^b   Tebar, Javier ^b   Vidal, José ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ESTROGEN DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOCORTICOID; INSULIN; MEGESTROL ACETATE; METFORMIN; PHENOTHIAZINE DERIVATIVE; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL RADIOGRAPHY; AGE DISTRIBUTION; ANAMNESIS; ARTERIAL PRESSURE; BALLOON; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES MELLITUS; DIAGNOSTIC TEST; DIET THERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; EVALUATION RESEARCH; GASTRIC BANDING; GENE MUTATION; HUMAN; HYPERTENSION; KINESIOTHERAPY; METABOLIC SYNDROME X; MONOTHERAPY; MORBIDITY; MORTALITY; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; POLYSOMNOGRAPHY; PREVALENCE; PROPHYLAXIS; SEX DIFFERENCE; SPAIN; SURGICAL TECHNIQUE; TREATMENT PLANNING;

EID: 34447274551     PISSN: 16966112     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (230)

1. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282: 1523-9.
2. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-9.
3. Calle EE, Rodríguez C, Walter-Thumbond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-38.
4. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004; 291: 1238-45.
5. Banegas JR, López-García E, Gutíerrez-Fisac JL, Guallar-Castillón J, Rodríguez-Artalejo F. A simple estimate of mortality attributable to excess weight in the European Union. Eur J Clin Nutr 2003; 57: 201-8.
6. Calle EE, Thun MJ, Petrelli JM, Rodríguez C, Wealth CW. Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-105.
7. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, Samet JM. Body-mass index and mortality in Korean men and women. New Engl J Med 2006; 355: 779-87.
8. Estudio prospectivo Delphi. Costes sociales y económicos de la obesidad y sus patologías asociadas. Madrid. Gabinete de estudios Bernard-Krief; 1999.
9. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Pérusse L, Snyder EE, Bouchard C. The human obesity gene map. The 2005 update. Obes Res 2006; 14: 529-644.
10. Martí A, Moreno-Aliaga MJ, Hebebrand J, Martínez JA. Genes lifestyles and obesity. Int J Obes Relat Metab Disord 2004; 28: S29-S36.
11. Palou A, Serra F, Bonet ML, Pico C. Obesity: molecular bases of a multifactorial problem. Eur J Nutr 2000; 39: 127-44.
12. Woods SC, Seely RJ, Poirte D, Schwartz MW. Signals that regulate food intake and energy homeostasis. Science 1998; 280: 1378-83.
13. Clapham JC, Arch JRS, Chapman H, Haynes A, Lister C, Moore GBT, et al. Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 2000; 406: 415-8.
14. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemicals aspects of leptin, ghrelin, adiponectin and resistin. Clin Chim 2004; 50: 1511-25.
15. Rosmond R. Role of stress in the patogenesis of the metabolic syndrome. Psychoneuroendocrinol 2005; 30: 1-10.
16. Adán C, Cabot C, Vilà R, Grasa MM, Masanés RM, Esteve M, et al. Oleoyl-estrone treatment affects the ponderostat setting differently in lean and obese Zucker rats. Int J Obes 1999; 23: 366-73.
17. Hammond LE, Gallagher PA, Wang S, Hiller S, Kluckman KD, Posey-Marcos EL, et al. Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition. Mol Cell Biol 2002; 22: 8204-14.
18. Villena JA, Roy S, Sarkadi-Nagy E, Kim K-H, Sul HS. Desnutrin, and adipocyte gene encoding a novel patatin domain-containing protein, is induced byfasting and glucocorticoids. J Biol Chem 2004; 279:47066-75.
19. Rossner S. Can obesity be an infectious disease? Lakartidningen 2005; 102: 1896-8.
20. Dhurandhar NV, Israel BA, Kolesar JM, Mayhew GF, Cook ME, Atkinson RL. Increased adiposity in animals due to a human virus. Int J Obesity 2000; 24: 989-96.
21. Gallou-Kabani C, Junien C. Nutritional epigenomics of metabolic syndrome: new perspective against the epidemic. Diabetes 2005; 54: 1899-906.
22. Martí A, Moreno-Aliaga MJ, Hebreband J, Martínez JA. Genes, lifestyles and obesity. Int J Obes Relat Metab Disord 2004; 28 Suppl 3: S29-36.
23. Rankinen T, Bouchard C. Genetics of food intake and eating behavior phenotypes in humans. Annu Rev Nutr 2006; 26: 413-34.
24. Bray G, Bouchard C, James WPT. Definitions and proposed current classifications of obesity. En: Bray G, Bouchard C, James WPT (eds). Handbook of obesity. New York: Marcel Dekker; 1998: 31-40.
25. Sociedad Española para el Estudio de la Obesidad (SEEDO). Consenso español 1995 para la evaluación de la obesidad y para la realización de estudios epidemiológicos. Med Clin (Barc) 1996; 107: 782-7.
26. WHO. Programme of Nutrition, Family and Reproductive Health. Obesity. Preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva, 3-5 June, 1997. Geneva: WHO; 1998.
27. Cole TJ, Bellizi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-3.
28. Serra-Majem LI, Ribas Barba L, Aranceta Bartrina J, Pérez Rodrigo C, Saavedra Santana P, Peña Quintana L. Obesidad infantil y juvenil en España. Resultados del Estudio Enkid (1998-2000). Med Clin (Barc) 2003; 121: 725-32.
29. Gutiérrez-Fisac JL, López E, Banegas JR, Graciani A, Rodríguez-Artalejo F. Prevalence of overweight and obesity in elderly people in Spain. Obes Res 2004; 12: 710-5.
30. Aranceta J, Pérez Rodrigo C, Muñoz M. Perfil nutricional de los ancianos institucionalizados en España. En: Muñoz M, Aranceta J, Guijarro JL (eds). Libro blanco de la alimentación del anciano en España. Madrid: Panamericana; 2004.
31. Aranceta J, Pérez Rodrigo C, Foz Sala M, Mantilla T, Serra Majem L, Moreno B, Monereo S, Millán J; Grupo Colaborativo para el estudío DORICA fase 2. Tablas de evaluación del riesgo coronario adaptadas a la población española: Estudio DORICA. Med Clin (Barc) 2004; 123: 686-91.
32. Aranceta J, Pérez C, Marzana I, Eguileor I, González de Galdeano L, Saenz de Buruaga J. Encuesta de Nutrición de la Comunidad Autónoma Vasca. Tendencias de consumo alimentario, indicadores bioquímicos y estado nutricional de la población adulta de la Comunidad Autónoma Vasca. Vitoria: Gobierno Vasco; 1994.
33. Aranceta J, Pérez C, Amela C, García R. Encuesta de Nutrición de la Comunidad de Madrid. Documentos Técnicos de Salud Pública no 18. Dirección General de Prevención y Promoción de la Salud, Comunidad de Madrid. Madrid; 1994.
34. Martínez-Ros MT, Tormo MJ, Navarro C, Chirlaque MD, Pérez-Flores D. Extremely high prevalence of overweight and obesity in Murcia, a Mediterranean region in south-east Spain. Int J Obes Relat Metab Disord 2001; 25: 1372-80.
35. Mataix Verdú J, Llopis González J, Martínez de Victoria E, Montellano Delgado MA, López Frías M, Aranda Ramírez P. Valoración del estado nutritional de la Comunidad Autónoma de Andalucía. Granada: Dirección General de Salud Pública y Participación de la Junta de Andalucía, Instituto de Nutrición y Tecnología de Alimentos de la Universidad de Granada, Escuela Andaluza de Salud Pública; 1999.
36. Serra Majem L, Ribas Barba L, García Closas R, Ramón Torrell JM, Salvador Castell G, Farran Codina A, et al. Avaluació de l'estat nutricional de la població catalana (1992-93). Avalauació dels hàbits alimentaris, el consum d'aliments, energia i nutrients, i de l'estat nutritional mitjançant indicadors bioquímics i antropomètrics. Barcelona: Generalitat de Catalunya. Departament de Sanitat i Seguretat Social; 1996.
37. Serra Majem Ll. Encuesta Nutricional de Canarias, ENCA, 1997-1998. (Vol. 1-5). Servicio Canario de Salud. Santa Cruz de Tenerife; 1999-2000.
38. Tojo Sierra R, Leis Trabazo R. Estudio Galinut. Santiago de Compostela: Conselleria de Sanidad- Departamento de Pediatría; 1999.
39. Tur JA, Obrador A (dirs). Estudio de Nutrición de las Islas Baleares. (ENIB, 1999 - 2000). Libro blanco de la alimentación y la nutrición en las Islas Baleares. Volumen I. Rev Cien IEB 2002; 27:1-120.
40. Vioque J, Quiles J. Encuesta de nutrición y salud de la Comunidad Valenciana, 1994. Alicante: Departamento de Salud PúblicaUniversidad Miguel Hernández; 2003.
41. Aranceta Bartrina J, Pérez Rodrigo C, Serra Majem LI, Ribas Barba L, Quiles Izquierdo J, Vioque J, et al y Grupo Colaborativo SEEDO. Prevalencia de obesidad en España. Resultados del estudio SEEDO 2000. Med Clin (Barc) 2003; 120: 608-12.
42. Aranceta Bartrina J, Serra Majem LL, Foz-Sala M, Moreno Estaban B y grupo colaborativo SEEDO. Prevalencia de obesidad en España. Med Clin (Barc) 2005; 125: 460-6.
43. Hernández M, Castellet J, Narvaiza JL, Rincón JM, Ruiz I, Sánchez E, et al (1988). Curvas y tablas de crecimiento. Instituto sobre crecimiento y desarrollo fundación F. Orbegozo. Madrid: Garsi.
44. Rubio MA, Gómez de la Cámara A, Del Campo J, Jurado C, García JD, Gómez-Gerique JA, et al. Prevalencia de obesidad en Espana tras 14 años de seguimiento de la cohorte DRECE. Endocr Nutr 2006; 53 (supl 1): 86.
45. Gutiérrez-Fisac JL, Regidor E, Banegas JR, Rodríguez- Artalejo F. Prevalencia de obesidad en la población adulta española: 14 años de crecimiento continuado. Med Clin (Barc) 2005; 124: 196-7.
46. Aranceta Bartrina J. Epidemiología de la obesidad mórbida en España. En: Rubio MA (ed) Manual de obesidad mórbida. Madrid: Editorial Médica Panamericana; 2006. pp. 37-45.
47. Aranceta Bartrina J, Serra Majem LI, Ribas Barba L, Pérez Rodrigo C. Factores determinantes de la obesidad en la población infantil y juvenil española. En: Serra Majem LI, Aranceta Bartrina J (eds). Obesidad infantil y juvenil. Estudio enKid. Barcelona: Editorial Masson; 2001: 109-28.
48. Aranceta J, Pérez-Rodrigo C, Serra-Majem LI, Ribas L, Quiles-Izquierdo J, Vioque J, Foz M, et al. Influence of sociodemographic factors in the prevalence of obesity in Spain. The SEEDO'97 Study. Eur J Clin Nutrition 2001; 55: 430-5.
49. Gutiérrez-Fisac JL, Regidor E, Banegas Banegas JR, Rodríguez Artalejo F. The size of obesity differences associated with educational level in Spain, 1987 and 1995/97. J Epidemiol Community Health 2002; 56: 457-60.
50. Onat A, Avci GS, Barlan MM, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004; 28: 1018-25.
51. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE. Abdominal adiposity and coronary heart disease in women. JAMA 1998; 280: 1843-48.
52. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al and INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
53. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al, and INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-49.
54. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73: 460-8.
55. Onat A, Avci GS, Barlan MM, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 2004; 28: 1018-25.
56. Concepción L, Martí-Bonmatí L, Aliaga R, Delgado F, Morillas C, Hernandéz A. Estudio de la grasa abdominal mediante resonancia magnética: comparación con parámetros antropométricos y de riesgo cardiovascular. Med Clin (Barc) 2001; 117: 366-9.
57. Examination Committee of Criteria for "Obesity Disease" in Japan. New criteria for obesity disease in Japan. Circ J 2002; 66: 987-92.
58. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Geneva: Department of Non-communicable Disease Surveillance, World Health Organization, 1999.
59. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
60. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
61. Alberti KGMM, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome -a new worldwide difinition. Lancet 2005; 366: 1059-62.
62. García-Lorda P, Bulló M, Balanzà R, Salas-Salvadó J. C-reactive protein, adiposity and cardiovascular risk factors in a Mediterranean population. Int J Obes 2006; 30: 468-74.
63. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
64. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-59.
65. Martínez-Larrad MT, Fernández-Pérez C, Sànchez JL, López A, Fernández-Álvarez J, Riviriego J, et al. Prevalencia del síndrome metabólico (criterios ATP-III). Estudio de base poblacional en áreas rural y urbana de la provincia de Segovia. Med Clin (Barc) 2005; 125: 481-6.
66. Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, Gabriel R, Williams K, Gómez-Gerique JA, et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 2003; 11: 1480-7.
67. Álvarez León EE, Ribas Barba L, Serra Majem L. Prevalencia del sindrome metabólico en la población de la Comunidad Canaria. Med Clin 2003; 120: 1724.
68. Ascaso JF, Romero P, Real JT, Lorente RI, Martínez-Vails J, Carmena R. Abdominal obesity, insulin-resistance, and metabolic syndrome in a southern European population. Eur J Intern Med 2003; 14: 101-6.
69. Aranceta J, Pérez Rodrigo C, Serra Majem LI, Vioque J, Tur Marí JA, Mataix Verdú J, et al. Estudio DORICA: Dislipemia, obesidad y riesgo cardiovascular. En: Aranceta J, Foz M, Gil B, Jover E, Mantilla T, Millán J, Monereo S, Moreno B (eds). Obesidad y riesgo cardiovascular. Estudio DORICA. Madrid: Editorial Médica Panamericana; 2004. pp. 125-156.
70. Troiano RP, Fronguillo EA Jr, Sobal J, Levitsky DA. The relationship between body weight and mortality: a quantitative analysis of combined information from existing studies. Int J Obes Relat Metab Disord 1996; 20: 63-75.
71. Manson JE, Stampfer MJ, Hennekens CH, Willet WC. Body weight and longevity. A reassessment. JAMA 1987; 257: 353-8.
72. Bautista-Castaño I, Molina-Cabrillana J, Montoya-Alonso JA, Serra-Magem L. Factores de riesgo cardiovascular en el sobrepeso y la obesidad: variaciones tras tratamiento de pérdida ponderal. Med Clin (Barc) 2003; 121: 485-91.
73. Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Gonatakis ES, Symeonidis AN, et al. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METSGREECE multicentre study. Curr Med Res Opin 2004; 20: 1691-1701.
74. Stevens J, Cai J, Pamuk ER, Williamson DF, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med 1998; 338: 1-7.
75. Ajani UA, Loufo PA, Gaziano JM, Lee IM, Spelsberg A, Buring JE, Willet WC, Manson JE. Body mass index and mortality among US male physicians. Ann Epidemiol 2004; 14: 731-9.
76. Blackberry I, Kouris-Blazos A, Wahlqvist ML, Steen B, Lukito W, Horie Y. Body mass index is not a significant predictor of survival amongst older people. Asia Pac J Clin Nutr 2004: 13 (Suppl): S137.
77. Heiat A, Vaccarino V, Krumholz HM. An evidence-based assessment of federal guidelines for overweight and obesity as they apply to elderly persons. Arch Intern Med 2001; 16: 1194-203.
78. Elia M. Obesity in the elderly. Obes Res 2001; 9 (Suppl. 4): 244S-8S.
79. National Heart Lung and Blood Institute: Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998; 6: S51-S210.
80. Avenell A, Brown TJ, McGee MA, Campbell MK, Grant AM, Broom J, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet 2004; 17: 317-35.
81. Finer N. Low-calorie diets and sustained weight loss. Obes Res 2001; 9: 290S-4S.
82. Pirozzo S, Summerbell C, Cameron C, Glasziou P. Should we recommend low-fat diets for obesity? Obes Rev 2003; 4: 83-90.
83. Nordmann AJ, Nordmann A, Briel M, Keller U, Nancy WS, Brehm BJ, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors. A meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166: 285-93.
84. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 2005; 293: 43-53.
85. Riccardi G, Giaccob R, Rivellese AA. Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 2004; 23: 447-56.
86. Reddy ST, Wang CY, Sakhaee K, Brinkley L, Pack CY. Effect of low-carbohydrate high protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis 2002; 40: 265-74.
87. Abete I, Parra MD, Zulet MA, Martínez JA. Sifferent dietary strategies fofr weight loss in obesity: role of energy and macronutrient content. Nutr Res Rev 2006; 19: 5-17.
88. Mustajoki P, Pekkarinen T. Very low energy diets in the treatment of obesity. Obes Res 2001; 2: 61-72.
89. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 2001; 74: 579-84.
90. Lantz H, Peltonen M, Agren L, Torgerson JS. Intermittent versus on-demand use of a very low caloric diet: a randomized 2-year clinical trial. J Int Med 2003; 253: 463-71.
91. Quin Rothacker D. Five-year self-managemet of weight using meal replacements: comparison with matched controls in rural Wisconsin. Nutrition 2000; 16: 344-8.
92. Keogh JB, Clifton PM. The role of meal replacements in obesity treatment. Obes Rev 2005; 6: 229-34.
93. Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four-year results. Obes Res 2000; 8: 399-402.
94. Heymsfield SB, van Mierlo CAJ, van der Knaap HCM, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes 2001; 27: 537-49.
95. Garrow J, Summerbell C. Meta-analysis: effects of exercise, with or without dieting, on body composition of overweight subjects. Eur J Clin Nutr 1995; 49: 1-10.
96. Miller WC, Koceja DM, Hamilton EJ. A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes 1997; 21: 941-7.
97. Jakicic JM, Otto AD. Physical activity considerations for the treatment and prevention of obesity. Am J Clin Nutr 2005; 82 (suppl): 226S-9S.
98. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995; 273: 402-7.
99. US Department of Health and Human Services and U.S. Department of Agriculture. Dietary Guidelines for Americans 2005. www.healthierus.gov/ dietaryguidelines (acceso 10 de octubre de 2006).
100. st Stock Conference and consensus statement. Obes Rev 2003; 4: 101-14.
101. Jakicic JM, Clark K, Coleman E, Foreyt J, Melanson E, Volek J, et al. American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2001; 33: 2145-56.
102. Jeffery RW, Wing RR, Sherwood NE, Tate DF. Physical activity and weight loss: does prescribing higher physical activity goals improve outcome? Am J Clin Nutr 2003; 78: 684-9.
103. Robles F, Escobar K, Cano J. Andar es vivir+. Madrid: Ediciones Tutor S.A; 2004.
104. Mcinnis KJ, Frankilin BA, Rippe JM. Counseling for Physical Activity in Overweight and Obese Patients. Am Fam Physician 2003; 67: 1249-56.
105. Wadden TA, McGuckin BG, Rothman RA, Sargent SL. Lifestyle Modification in the Management of Obesity. J Gastroenterol 2004; 7: 452-63.
106. Foster GD, Makris AP, Bailer BA. Behavioral treatment of obesity. Am J Clin Nutr 2005; 82 (suppl): 230S-5S.
107. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353: 2111-20.
108. Spitzer RL, Devlin M, Walsh BT, Hasin D, Wing R, Marcus MD, et al. Binge eating disorder: a multisided field trial of the diagnostic criteria. Int J Eat Disord 1992; 11: 191-203.
109. Elfhag K, Rössner S. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain. Obes Rev 2005; 6: 67-85.
110. Guerciolini R. Mode of acting of orlistat. Int J Obes Relat Metab Disord 1997; 1 (Supl 1): 12S-23S.
111. Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461-8.
112. O'Meara, et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004; 5: 51-68.
113. Padwall R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes 2003; 27: 1437-46.
114. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-46.
115. Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet. Early response to treatment predicts weight maintenance. Diab Obes Metabol 2005; 7: 699-708.
116. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004; 164: 1395-404.
117. Kelley DE, Kuller LH, McKolanis TM, Harper T, Mancino J, Kalhan S. Orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes mellitus. Diabetes Care 2004; 27: 33-40.
118. Damci T, Yalin S, Balci H, Osar Z, Korugan U, Ozyazer M, Ilkova M. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 2004; 27: 1077-80.
119. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) Study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
120. Mittendorfer B, Ostlund RE, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001; 9: 599-604.
121. Hsieh CJ, Wang PW, Liu RT, Tung SC, Chien WY, Chen JF, et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract 2005; 67: 78-83.
122. Tiikkainen M, Bergholm R, Rissanen A, Aro A, Salminen I, Tamminen M, et al. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am J Clin Nutr 2004; 79: 22-30.
123. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004; 27: 33-40.
124. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Curie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-44.
125. Sutera PM, Marmiera G, Veya-Linderb C, Hänselerc E, Lentzb J, Vettera W, Otvos J. Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size. Atherosclerosis 2005; 180: 127-35.
126. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, et al. Three month tolerability of orlistat in adolescents with obesity related comorbid conditions. Obes Res 2002; 10: 642-50.
127. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents. A randomized controlled trial. JAMA 2005; 293: 2873-83.
128. Hansen D, Toubro S, Stock M, MacDonald I, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998; 68: 1180-6.
129. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994-1003.
130. Milano W, Petrella C, Casella A, Capasso A, Carrino S, Milano L. Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther 2005; 22: 25-31.
131. Apfelbaum M, Yague P, Ziegles O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179-84.
132. Mathus-Vliegen EM, Balance Study Group. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. Eur J Clin Nutr 2005; 59 Suppl 1: S31-9.
133. Godoy-Matos A, Carraro L, Vieira A, Oliveira J, Guedes EP, Mattos L, Rangel C, Moreira RO, Coutinho W, Appolinario JC. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005; 90: 1460-5.
134. Berkowitz RL, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity. A randomized controlled trial. JAMA 2003; 289: 1805-12.
135. Reisler G, Tauber T, Afriat R, Bortnik O, Goldman M. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. Isr Med Assoc J 2006; 8: 30-2.
136. Berkowitz RI, Fujikova K, Daniels SR, Hopping AG, Owen S, Perry AC, et al. Effects of sibutramine treatment in obese adolescents. A randomized trial. Ann Inter Med 2006; 145: 81-90.
137. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group (Sibutramine Trial of Obesity Reduction and Maintenance). Lancet 2000; 356: 2119-25.
138. Gaciong Z, Placha G. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study. J Hum Hypertens 2005; 19: 737-43.
139. DiMarzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosc 2005; 8: 585-9.
140. VanGaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-97.
141. Despres JP, Golay A, Sjostrom L, for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-34.
142. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, for the RIO Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight and obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368: 1660-72.
143. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, for the RIO-North American Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-75.
144. STRADIVARIUS (Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabant - the Intravascular Ultrasound Study). Available at: http://www.clinicaltrials.gov/ ct/gui/show/NCT00124332?order_2. Acceso 10 de octubre de 2006.
145. De Villar NGP, Loria V, Monereo S, ennombre del Grupo de Obesidad de la SEEN. Tratamientos "alternativos" de la obesidad: mito y realidad. Med Clin (Barc) 2003; 121: 500-10.
146. Pittler MH, Ernst E. Complementary therapies for reducing body weight: a systematic review. Int J Obes 2005; 25: 1030-8.
147. Pories WJ, MacDonald KG, Morgan EJ, Sinha MK, Dohm GL, Swanson MS, et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr 1992; 55 (suppl 2): 582S-5S.
148. Sjȯström CD, Lissner L, Wedel H, Sjȯström L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS intervention study. Obes Res 1999; 7: 477-84.
149. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al and the Swedish Obese Subjects Study Scientific Group.Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-93.
150. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahr-bach K, et al. Bariatric Surgery: a systematic review and metaanalysis. JAMA 2004; 292: 1724-37.
151. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugarman HJ, Livingston EH, et al. Meta-Analysis: Surgical Treatment of Obesity. Ann Intern Med 2005; 142: 547-59.
152. Rubio MA, Martínez C, Vidal O, Larrad A, Salas-Salvadó J, Pujol J, Díez I, Moreno B. Documento de consenso sobre cirugía bariátrica. Rev Esp Obes 2004; 4: 223-49.
153. Baltasar A, Bou R, Arlandis F, Martínez R, Serra C, Bengochea M, et al. Vertical banded gastroplasty at more than five years. Obes Surg 1998; 8: 29-34.
154. Arribas del Amo D, Aguilella Diago V, Elia Guedea M, Artigas Marco C, Martínez Díez M. Resultados a largo plazo de la gastroplastia vertical con banda en el tratamiento quirúrgico de la obesidad mórbida. Complicaciones específicas de la técnica quirúrgica. Cir Esp 2001; 70: 227-30.
155. Dargent J. Laparoscopic adjustable gastric banding: Lessons from the first 500 patients in a single institution. Obes Surg 1999; 9: 446-52.
156. Vetruyen M. Experience with lap-band system up to 7 years. Obes Surg 2002; 12: 569-72.
157. Almogy G, Crookes PF, Anthone GJ. Longitudinal gastrectomy as a treatment for the high-risk superobese patient. Obes Surg 2004; 14: 492-7.
158. Roa P, Kaidar-Person O, Pinto D, Cho M, Szomstein S, Rosenthal R. Laparoscopic sleeve gastrectomy as treatment for morbid obesity: technique and short-term outcome. Obes Surg 2006; 16: 1323-6.
159. Mognol P, Chosidow D, Marmuse J. Laparoscopic sleeve gastrectomy as an initial bariatric operation for high-risk patients: initial results in 10 patients. Obes Surg 2005; 15: 1030-3.
160. Langer FB, Bohdjalian A, Felberbauer FX, Fleischmann E, Reza Hoda MA, Ludvik B, et al. Does gastric dilatation limit the success of sleeve gastrectomy as a sole operation for morbid obesity? Obes Surg 2006; 16: 166-71.
161. Silecchia G, Boru C, Pecchia A, Rizzello M, Casella G, Leonetti F, Basso N. Effectiveness of laparoscopic sleeve gastrectomy (first stage of
162. Brolin RE. Gastric bypass. Surg Clin North Am 2001; 81: 1077-95.
163. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y 500 patients: technique and results, with 3-60 month follow-up. Obes Surg 2000; 10: 233-9.
164. Nguyen NT, Goldman Ch, Rosenquist CJ, Arango A, Cole CJ, Lee SJ, et al. Laparoscopic versus open gastric bypass: a randomised study of outcomes, quality of life and costs. Ann Surg 2001; 234: 279-91.
165. Podnos YD, Jiménez JC, Wilson SE, Stevens M, Nguyen NT. Complications alter laparoscopic gastric bypass. Arch Surg 2003; 138: 957-61.
166. Scopinaro N, Adami AF, Marinari GM, Gianetta E, Traverso E, Friedman E, et al. Biliopancreatic diversion. World J Surg 1998; 22: 936-46.
167. Baltasar A. Cruce duodenal. Cir Esp 2004; 75: 259-66.
168. Sánchez-cabezudo C, Larrad A, Ramos I, Moreno B. Resultados a 5 años de la derivación biliopancreática de Larrad en el tratamiento de la obesidad mórbida. Cir Esp 2001; 70: 133-41.
169. Bloomberg RD, Fleishman A, Nalle JE, Herron DM, Kini S. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg 2005; 15: 145-54.
170. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-37.
171. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livinston EH, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142: 547-59.
172. Christou NV, Sampalis JS, Lieberman M, Look D, Auger S, McLean AP, McLean LD. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg 2004; 240: 416-23.
173. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-93.
174. Genco A, Bruni T, Doldi SB, Forestieri P, Marino M, Busseto L, et al. BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients. Obes Surg 2005; 15: 1161-4.
175. Genco A, Cipriano M, Bacci V, Cuzzolaro M, Materia A, Raparelli L, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes 2005; 2006; 30: 129-33.
176. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005; 61: 19-27.
177. Herve J, Wahlen CH, Schaeken A, Dallemagne B, Dewandre JM, Markiewicz S, et al. What Becomes of Patients One Year after the Intragastric Balloon has been Removed? Obes Surg 2005; 15: 864-70.
178. Alfalah H, Philippe B, Ghazal F, Jany T, Arnalsteen L, Romon M, et al. Intragastric balloon for preoperative weight reduction in candidates for laparoscopic gastric bypass with massive obesity. Obes Surg 2006; 16: 147-50.
179. Chen J. Mechanisms of action of the implantable gastric stimulator for obesity. Obes Surg 2004; 14: S28-S32.
180. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 1999; 16: 716-30.
181. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-65.
182. UK Prospective Diabetes Study Group UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.
183. Sheen A. Current maagement strategies for coexisting Diabetes Mellitus and Obesity. Drugs 2003; 63: 1165-84.
184. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002; 162: 1867-72.
185. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Hypertension 2003; 42: 1206-52.
186. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
187. Lindhom LH, Dahlof B, Edelman JM, Visen H, Borch-Jonsen K, Olsen MH, et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362: 619-20.
188. Yusuf S, Sleight P, Poque J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342: 145-53.
189. Caterson ID, Hubbard V, Bray GA, Grunstein R, Hansen BC, Hong Y, Labarthe D, Sidell JC, SmithSC. Obesity, a worldvide epidemic related to heart disease and stroke. Group III: Worldwide comorbidities of obesity. Circulation 2004; 110: e476-e83.
190. Vastag B. Obesity is now on everyone's plat. JAMA 2004; 291: 1186-8.
191. WHO technical report series (916). Recommendations for preventing excess weight gain and obesity. En: "Diet, nutrition and the prevention of chronic diseases: report of a joint WHO/FAO expert consultation". Joint WHO/FAO Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases (2002: Geneva, Switzerland): 61-71.
192. Morabia A, Costanza MC. Does walking 15 minutes per day keep the obesity epidemic away? Simulation of the efficacy of a populationwide campaign. Am J Public Health 2004; 94: 437-40.
193. Swinburn BA, Caterson I, Seidell JC, James WPT. Diet, nutrition and the prevention of excess weight gain and obesity. Public Health Nutrition 2004; 7: 123-46.
194. Mullis RM, Blair SN, Aronne LJ, Bier DM, Denke MA, Dietz W, Donato KA, Drewnowski A, French SA, Howard BV, Robinson TN, Swinburn B, Wechsler H. Obesity, a worldwide epidemic related to hearth disease and stroke. Group IV: prevention/treatment. Circulation 2004; 110: e484-e8.
195. Speiser PW, Rudolf MC, Anhalt H, et al. Childhood obesity. J Clin Endocrinol 2005; 90: 1871-87.
196. McLean N, Griffin S, Toney K, Hardeman W. Family involvement in weight control, weight maintenance and weight-loss interventions: a systematic review of randomised trials. Int J Obes 2003; 27: 987-1005.
197. Binns HJ, Ariza AJ. Guidelines help clinicians. Identify risk factors for overweight in children. Pediatr Ann 2004; 33: 18-22.
198. Marquillas JB, Sánchez-Ventura JG, Bosch JP, Domínguez JD. Prevención y promoción de la salud en la infancia y la adolescencia. Atención Primaria 1999; 24: 20-65.
199. Martin J. The National School Lunch Program - a continuing commitment. J Am Diet Assoc 1996; 96: 857-8.
200. Fitzgibbon ML, Stolley MR. Environmental changes. May be needed for prevention of overweight in minority children. Pediatr Ann 2004; 33: 45-9.
201. Lobstein T, Baur L, Uauy R for the IASO International Obesity Task Force. Obesity in children and young people: a crisis in public health. Obes Rev 2004; 5 (Suppl. 1): 4-85.
202. Dolan M, Weiss, Joyce M, Pietrobelli A, Heo M, Faith M. "Take the stairs instead of the elevator": Effects of environmental prompts on community stair use. NAASO's 2004 Annual Meeting. Las Vegas 2004: A161.
203. García RC, Sánchez-Pinilla RO, Peña CC, García DF, Adell MN. Recomendaciones sobre el estilo de vida. Atención Primaria 1999; 24: 118-32.
204. Tirodkar MA, Jain A. Food messages on African American television shows. Am J Public Health 2003; 93: 439-41.
205. López de la Torre M. Internet y Endocrinología. Endocr Nutr 2004; 51: 67-76.
206. a Asamblea mundial de la Salud 2004. http://www.who.int/dietphysicalactivity/en/ (acceso 10 octubre de 2006).
207. Allison DB, Webers MT. Treatment and prevention of obesity: What works, what doesn't work, and what might work. Lipids 2003; 38: 147-55.
208. Agencia española de Seguridad Alimentaria. Estrategia NAOS. Invertir la tendencia de la obesidad Madrid 2005, Ministerio de Sanidad y Consumo.
209. Gordon R. An operational classification of disease prevention. In: JA Steinberg and MM Silverman, eds. Preventing mental Disorders: A research perspective VS. Department of Health and Human Services. Washington DC: Governement Printing Office 1987: 20-6.
210. Swinburn BA, Egger G. Preventive strategies against weight gain and obesity. Obes Rev 2002; 3: 289-301.
211. Carraro R, Cebrián MG. Role of prevention in the contention of the obesity epidemic. Eur J Clin Nutr 2003; 57 (Suppl 1): S94-S96.
212. Dennison BA, Boyer PS. Risk evaluation in pediatric practice. Pediatr Ann 2004; 33: 25-30.
213. Darnton-Hill, Nishida C, James WPT. A life course approach to diet, nutrition and the prevention of chronic diseases. Public Health Nutrition 2004; 7: 101-21.
214. Rich-Edwards JW, Colditz GA, Stampfer MJ, Willet WC, Gillman MW, Hennekens CH, et al. Birthweight at the risk for type 2 diabetes mellitus in adult women. Ann Intern Med 1999; 130: 278-84.
215. Thibault H, Rolland-Cachera MF. Stratégies de prévention de l'obésité chez lénfant. Arch Ped 2003; 20: 1100-8.
216. Himes JH, Dietz WH. Guidelines for overweight in adolescent preventive services: recommendations from an expert committee. Am J Clin Nutr 1994; 59: 307-16.
217. Robinson T. Reducing children's television viewing to prevent obesity: a randomized controlled trial. JAMA 1999; 282: 1561-7.
218. Proctor MH, Moore LL, Gao D, Cupples LA, Bradlee ML, Hood MY, Ellison RC. Television viewing and change in body fat from preschool to early adolescence: the Framingham children's study. Int J Obes 2003; 27: 827-33.
219. Andersen RE, Crespo CJ, Barlett SJ, Cheskin LJ, Pratt M Relationship of physical activity and television watching with body weight and level of fatness among children. JAMA 1988; 279: 938-42.
220. American Academy of Pediatrics. Policy Statement. Soft drinks in schools. Pediatrics 2004; 113: 152-4.
221. Neumark-Sztainer D. Obesity and eating disorder prevention: an integrated approach?. Adolescent Medicine 2003; 14: 159-73.
222. Neumark-Sztainer D, Hannan PJ, Story M, Perry ChL. Weight-control behaviors among adolescent girls and boys: implications for dietary intake. J Am Diet Assoc 2004; 104: 913-20.
223. Sothern M, Gordon S. Prevention of obesity in young children: A critical challenge for medical professionals. Clin Pediatr 2003; 42: 101-11.
224. Whitaker RC. Obesity prevention in pediatric Primare Care. Four behaviors to target. Arch Pediatr Adolesc Med 2003; 157: 725-7.
225. Sothern M, Gordon S. Prevention of obesity in young children: A critical challenge for medical professionals. Clin Pediatr 2003; 42: 101-11.
226. US Preventive Services Task Force. Screening for obesity in adults: Recommendations and rationale. Ann Intern Med 2003; 139: 930-2.
227. Arrizabalaga JJ, Calañas A, Vidal J, et al. Guía de práctica clínica para el manejo del sobrepeso y la obesidad en personas adultas. Endocrinol Nutr 2003; 50 (Supl 4): 1-38.
228. Arrizabalaga JJ, Masmiquel LL, Vidal J, et al. Recomendaciones y algoritmo de tratamiento del sobrepeso y la obesidad en personas adultas. Med Clin (Barc) 2004; 122: 104-10.
229. Mories MT, Astorga R, Soler J, et al. Criterios de derivación desde primaria a atención especializada de pacientes con obesidad. Criterios de buena atención especializada. Endocrinol Nutr 2005; 52 (Supl 1):38-9.
230. Bellido D. El paciente con exceso de peso: guía práctica de actuación en Atención Primaria. Rev. Esp Obes 2006; 4: 5-16.